BenNie

Pro free enterprise & anti-statism. Liberal , but not the kind that reach in to other people’s pockets.

[BenNie @nietsche]

Have you forgotten?

https://t.co/43R8TJ4oXq

[BenNie @nietsche]

@Edward_Blom Tack Edward. Dags att låsa in skräpet på riktigt.

[Lifespan @JoinLifespan]

Today, @lifebiosciences confirmed the first patient has been dosed with an epigenetic restoration drug candidate. An exciting milestone 🚀

Life Biosciences is the OG cellular rejuvenation using epigenetic restoration to reverse diseases of aging. It was cofounded by @davidasinclair, who serves as Chairman

The company’s proprietary Epigenetic Restoration platform utilizes three transcription factors, OCT4, SOX2, and KLF4 (OSK), to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, and has the potential to address a wide range of serious age-related diseases

The Phase 1 trial will evaluate the safety and tolerability of ER-100, with additional endpoints assessing visual function. ER‑100 is the first clinical candidate from Life Bio’s Epigenetic Restoration platform, which uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK) to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression

“This is an important moment for Life Bio and for the field of aging biology,” said David Sinclair, Ph.D., Co‑founder of Life Biosciences and Professor of Genetics at Harvard Medical School. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.”

Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential.

“This milestone reflects years of rigorous scientific development and translational research,” said Sharon Rosenzweig‑Lipson, Ph.D., Chief Scientific Officer of Life Biosciences. “Our preclinical studies have demonstrated that controlled OSK expression can reset epigenetic patterns associated with healthy cellular function, improve tissue performance, and restore visual function in animal models. Advancing ER‑100 into the clinic is an important step toward translating epigenetic restoration into a new class of medicines for age-related diseases.”

Optic neuropathies represent a large unmet medical need. Current treatments primarily address risk factors, such as intraocular pressure in glaucoma, but do not directly target the damage to retinal ganglion cells. As a consequence, the disease often leads to irreversible vision loss despite treatment

Vision loss not only directly impacts patients’ lives, but also increases the risk of loss of independence, damaging falls, and depression and dementia due to social isolation, underscoring the need for disease-modifying therapies.

Beyond ER‑100, Life Bio is developing applications of its proprietary Epigenetic Restoration platform for multiple indications in a variety of organs, reflecting the broad therapeutic potential of this platform.

About Optic Neuropathies Optic neuropathies are a group of disorders characterized by damage to retinal ganglion cells (RGCs), the primary neurons connecting the eye to the brain. Because RGCs do not naturally regenerate, damage results in permanent vision impairment. One such optic neuropathy, open-angle glaucoma (OAG) is a chronic neurodegenerative disease and a leading cause of blindness in older adults

While often associated with elevated intraocular pressure, disease progression frequently continues despite treatment, and some patients suffer from OAG despite normal intraocular pressure. Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over fifty. It involves sudden, painless vision loss due to insufficient blood flow, for which there are currently no approved treatments

About ER-100 ER‑100 is an investigational therapy in clinical development for the treatment of optic neuropathies including OAG and NAION. ER‑100 is designed to restore function in retinal ganglion cells using Life Biosciences’ Epigenetic Restoration platform, which utilizes controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK), to reset cellular gene expression patterns and restore cells to a more youthful and functional state. ER‑100 is currently being evaluated in a Phase 1 clinical trial. More information can be found at https://t.co/GDRzIctoot (NCT07290244): https://t.co/Jj9cnu2M6w

For more information, visit https://t.co/msih0JTYfF or follow on social media
https://t.co/pEGPJjFjnQ

[BenNie @nietsche]

@SternStefan Det är bäst för Sverige att inse att varesig staten eller myndigheter har ansvar - endast MÄNNISKOR har ansvar.

[BenNie @nietsche]

Enig

[Stefan Stern @SternStefan]

Helt enig.

[BenNie @nietsche]

@JHuitfeldt Fenomenalt journalistiskt tänk och genomförande. Det är ett sant nöje att följa er utveckling. Bra teamwork!!

[Richard Herrey @RichardHerrey]

Då var vi här igen Magdalena Andersson. Hittepå om Skåne sjukvård.
Först var det lögnen om 1000 personer som skulle avskedas. Nu mjuka tvättlappar för bebisar som enligt henne sparats in. Verksamhetschef bekräftar att tidigare tvättlappar dragits in pga att de innehåller glasfiber, INTE pga besparing.
Hittepå för maximal emotionell effekt, utan att ha koll på fakta, verkar vara Anderssons melodi.
https://t.co/3Rk88OJt8a

[David Sinclair @davidasinclair]

Good news: Another study showing that fasting can help cancer patients. A 16 hour fast enhanced the cancer-killing activity of T cells and synergized with immunotherapy to reduce tumor size, ostensibly by causing cancer cells to release the amino isoleucine... 🧵

[BenNie @nietsche]

håller med Stefan Stern… intressant, väldigt intressant…

[Stefan Stern @SternStefan]

Intressant. När Redar tonar ner ”S-folkblandningen”, så åker Aftonbladet till Göteborg. S-VU:s nye ledamot Attenius intygar att byggandet av hyresrätter för socioekonomiskt svaga där redan är i full gång i ännu fungerande villaområden. S-väljargrupperna utlovas ”få komma ikapp.”

[BenNie @nietsche]

@SternStefan Intressant att läsa. Det är ett uppenbart signalspråk till de egna leden som är fyllda av kommunister, socialister, vänsterliberala och i allmänhet ekonomiskt okunniga individer…

[BenNie @nietsche]

@MbarkCherguia Man made = pond

[BenNie @nietsche]

@JHuitfeldt Enig! Fantastisk person.

[BenNie @nietsche]

@JoakimKpmlr @drdanielschatz Som är imperialistisk

[BenNie @nietsche]

Agreed! One of the best ever was…

[Derya Unutmaz, MD @DeryaTR_]

In my opinion, Milton Friedman was one of the best economists who ever lived:

“Consumers don't produce inflation. Producers don't produce inflation. Inflation is produced only by too much government spending and too much government creation of money, and nothing else.”

[David Sinclair @davidasinclair]

2025 highlights:
1. Showed age-reversal in liver & eye diseases
2. Advanced OSK therapy to first-in-human Q1 2026
3. Initiated international collabs
4. David Guyer joined as a director
5. Confirmed epigenetic reversal in primates

Exciting time to be alive!

[BenNie @nietsche]

@PeterSweden7 Nah… not really. I was there the other day. I did not see one kalashnikov, or a convoy of screaming primates with AK47s

[BenNie @nietsche]

@elonmusk When Sweden joined back in 1995 I said to my friends that EU is not a good choice since it is a new version of USSR 2.0… I’m still right

[BenNie @nietsche]

@kvartalet @hanifbali Hm. Inte alla sviker. Hälsar en boomer som är fyrbarnsfar ..

[Stefan Stern @SternStefan]

Uppfriskande från en av våra nyaste statsråd.

[BenNie @nietsche]

Intressant och välskriven artikel

[Elisabet Lann @IsaLann1]

Det är lögn att omtanke om den svage skulle vara vänster.

https://t.co/RDaFNlJv4m